Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What's Behind Japan Firms' Higher Approval Rates In Challenging Oncology, CNS Areas?

Alliances Play A Key Role

Executive Summary

Despite a global tendency for lower than average success rates from Phase I to approval in the challenging oncology and CNS areas, a recent Citeline study finds top Japanese pharma firms have relatively high rates in these two categories in the US. So what are the factors driving those differences?

You may also be interested in...



Otsuka Adds To CNS Pipeline With Mindset Acquisition

After a year of R&D collaboration, Otsuka has made a decision to acquire Canadian venture Mindset to further expand its neurological pipeline with new 5-HT2A agonists.  

Quick Listen: Scrip's Five Must-Know Things

In this week's episode of Five Must-Know Things: Leqembi’s US treatment infrastructure; Novartis backs out of BeiGene deal; Transgene’s new CEO’s plans; Japanese firms’ R&D success; and a look at deal-making in the first half.

Leqembi Approval Opens Door To Alzheimer’s Market For Lilly And Others

Full approval for Leqembi is not only a breakthrough for Eisai and Biogen, it will also give companies and investors greater confidence in investing in more novel Alzheimer’s therapies.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel